

**PROTOCOLS, MEDICATIONS,  
AND DEVICES COMMITTEE  
MINUTES  
MAY 14, 2009  
150 N 18<sup>th</sup> Avenue, Conference Room 345-A**

**MEMBERS PRESENT**

John Gallagher, Chairman  
Janine Anderson  
Terence Mason

**MEMBERS-TELECONFERENCE**

Patricia Ellis  
Sue Kern  
Terry Shine  
Bruce Toliver

**MEMBERS ABSENT**

Steven Curry  
Marc Holyfield  
Charles Finch

**ADHS STAFF PRESENT**

Terry Mullins, Bureau Chief  
Ed Armijo, Deputy Bureau Chief  
Elizabeth Roig  
Joel Bunis  
Angie Cauthon  
Peggy Lahren  
Kim Briggs  
Robin Gil  
Noreen Adlin  
Larry Lorenzen

**I. CALL TO ORDER**

Meeting was called to order at 2:05 p.m. A quorum was present

**II. DISCUSS/AMEND/APPROVE MINUTES OF FEBRUARY 05, 2009**

Janine Anderson made a motion to approve the minutes, second by Terence Mason. The motion passed with a request that BEMSTS staff make grammatical corrections. Minutes are approved with corrections

**III. REPORTS**

**a. Chairman's Report**

John Gallagher, Chairman had nothing to report

**b. Bureau Chief's Report**

Terry Mullins, Bureau Chief reported that we are still waiting for the Legislature to approve the Agency Budget which will likely occur towards the end of June.

**IV. DISCUSSION AND ACTION ITEMS**

**a. Discuss and approve use of an LMA by BLS providers**

Bruce Toliver made a motion to approve the use of an LMA by BLS providers, seconded by Terence Mason. In discussion, the need for better terminology would reduce the need to revise rules when a new device is identified for use. The motion was approved and will be placed on the next MDC agenda.

**b. Discuss request by Raytheon to allow BLS Providers to administer topical Calcium Gluconate for hydrofluoric acid exposures**

Elizabeth Roig, Rules Analyst provided an overview of a request by Raytheon to allow its BLS providers to use Calcium Gluconate gel, once the

moratorium on rule writing expires, BEMSTS will seek to revise Table I and end the current pilot project of similar nature with Honeywell.

**c. Discuss and approve Atropine drug profile revision**

Patricia Ellis identified substantive corrections needed in the drug profile and made a motion to table the drug profile until the next meeting, seconded by Janine Anderson. The motion was approved. Patricia Ellis will make the required changes and send to BEMSTS.

**d. Discuss and approve Lorazepam drug profile revision**

Mary Anne Matter described the proposed changes, and others identified additional substantive changes necessary. Janine Anderson made a motion to table the drug profile until the next meeting, seconded by Terence Mason. The motion was approved. Maryanne will make the required changes and send to BEMSTS.

**e. Discuss and approve Magnesium Sulfate drug profile revision**

Mary Anne Matter described the proposed changes, and others identified additional substantive changes necessary. Janine Anderson made a motion to table the drug profile until the next meeting, seconded by Terence Mason. The motion was approved. Mary Anne will make the required changes and send to BEMSTS.

**V. CALL TO THE PUBLIC**

There was a call to the Public but no response

**VI. SUMMARY OF CURRENT EVENTS**

There were no current events to summarize

**VII. ANNOUNCEMENT OF NEXT MEETING – November 12, 2009 2:00 P.M.**

**VIII. ADJOURNMENT**

Meeting was adjourned at 2:33 p.m.

Minutes drafted by: Angie Cauthon

Minutes were approved by the PMD committee 11/12/2009